The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

"I'm not going to second-guess myself."Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like ...

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

The Biden-era proposal would have made the drugs much more affordable for those Medicare and Medicaid patients with obesity who do not have those illnesses, the Times reported. Medicare officials ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...

One state, North Dakota, has taken the interesting step of adding obesity medications to its ... extending coverage of GLP-s to Medicare, it would have likely kickstarted similar decisions in ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...